Print

RhuDex Clinical Development to Continue Following Feedback from Regulatory Authorities

2009-10-05

MediGene AG has received feedback from the UK MHRA (Medicines and Healthcare products Regulatory Agency) regarding the in-vitro studies conducted with RhuDex. Since these tests did not suggest any negative effects of RhuDex, the MHRA agreed to a continuation of the drug candidate's clinical development.
To read the complete press release, please see www.medigene.com.
Lund, October 5, 2009
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
For further information, please contact:
Göran Forsberg, VP Investor Relations & Business Development
Tel: +46 (0) 46 19 11 54
Notes to editors
About RhuDex(TM)
RhuDex(TM) is a novel, orally available compound for the treatment of rheumatoid arthritis, originating from Active Biotech's patented CD80 antagonists, out-licensed to MediGene AG. RhuDex(TM) is being developed as a disease-modifying drug for the treatment of rheumatic diseases.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 11:30 a.m. CET on October 5, 2009.

pdf



Back